

Tumark® biopsy site markers

Designed to provide long-term visibility.



Tumark biopsy site markers are designed to support clinicians and women across the breast health pathway – **with clarity, confidence and control.**

Visible

All markers are made from nitinol, a biocompatible titanium alloy used for implants that remains visible after tissue deployment.¹

In 85% of marker placements, physicians stated that the ultrasound visibility was good to excellent upon deployment.²

Intuitive

The ergonomic handle design allows single-handed use under ultrasound guidance.³

In 99% of procedures completed, physicians agreed the device was easy to use.²

Secure

Distinct and easily identifiable shapes.²

Markers expand upon deployment and anchor firmly in the tissue.³

Precise

91% of markers placed did not migrate, as measured on a post-procedure mammogram in the initial data collection study.²

All markers deployed accurately to the intended area in 30 ultrasound-guided cases.²

One biopsy, one marker

Why place a biopsy marker?

Placing a marker during every breast biopsy is now recognised as best practice by clinical guidelines across the world, including the EU and the UK. These guidelines highlight that markers are an essential part of ensuring the correct lesion is identified, tracked and removed where necessary.

'A marker should be placed into the tumour at biopsy, to ensure resection of the correct site and to enable pathological assessment of the surgical specimen.'

- *European Society for Medical Oncology (ESMO), 2019⁵*

'A marker is always placed after an MRI-guided biopsy, even if the lesion remains visible after biopsy. This confirms the correct location of the sampling but also allows performance of any subsequent intervention by means of the easier mammographic or US guidance.'


- *European Society of Breast Imaging (EUSOBI), 2020⁶*

'A marker (clip), with mammographic documentation of its position, is the safest way to facilitate communication within and between teams and to ensure the correct lesion is removed at surgery or to facilitate follow-up.'

- *National Health Service (NHS), UK, 2016⁷*


Adding clarity – whatever the diagnosis

Biopsy markers provide benefits in both malignant and benign cases. They allow clinicians to follow lesions accurately from identification through biopsy and surgery, while also simplifying follow-up for women with non-cancerous findings by preventing unnecessary re-biopsies.⁸



'...the use of the new Tumark Vision clip seems uncomplicated and reliable. Because of its roundish shape and hyperechogenic behaviour, the Tumark Vision clip is highly detectable in breast ultrasound. The 3D shape provides good visibility of the Tumark Vision clip which could be observed in all cases after application.'

- *Rüland et al, 2018⁴*



Tumark biopsy site markers

Tumark markers are designed for long-term visibility, with exceptional performance under ultrasound – including in both horizontal and vertical axes. Made from biocompatible nitinol, the 3D mesh structure expands on deployment to anchor securely in tissue. Five distinct shapes allow easy identification when multiple sites are biopsied.



Professional Q



Professional X



Professional U



Professional Vision



Eye

Part Number	Product	Length
Tumark Professional for use with Eviva 18G:		
TUMARK-E13-S-Q	Standard Q shape	132mm
TUMARK-E13-P-Q	Petite Q shape	135.5mm
TUMARK-E13-S-X	Standard X shape	129.5mm
TUMARK-E13-P-X	Petite X shape	133mm
TUMARK-E13-S-VISION	Standard Vision shape	129.5mm
TUMARK-E13-P-VISION	Petite Vision shape	133mm

Tumark Professional for use with Brevera 18G:		
TUMARK-BREV-S-Q	Standard Q shape	129.5mm
TUMARK-BREV-P-Q	Petite Q shape	125.5mm
TUMARK-BREV-S-X	Standard X shape	127.5mm
TUMARK-BREV-P-X	Petite X shape	123.5mm
TUMARK-BREV-S-VISION	Standard Vision shape	127.5mm
TUMARK-BREV-P-VISION	Petite Vision shape	123.5mm

For Ultrasound-guided Marking 18G:		
271510	Eye shape	100mm
271512	Eye shape	120mm
271559	U shape	100mm
271560	U shape	120mm
271589	Vision shape	100mm
271590	Vision shape	120mm

For MRI-guided Marking 18G:		
601570	U shape	120mm
601590	Vision shape	120mm

Delivery options that work for you

Tumark markers are compatible with all imaging modalities – including ultrasound, mammography and MRI – and are delivered via a system designed for precise placement across core needle and vacuum-assisted biopsy procedures.



Stereotactic biopsy site marker

With blunt tip for delivery through Eviva® and Brevera® biopsy introducers.



For percutaneous application


Sharp bevelled tip assists with introduction into the breast under ultrasound and MRI guidance.⁹

Hologic's Breast Health Continuum of Care

At Hologic, we know time is critical when it comes to the detection, diagnosis and treatment of breast cancer. We strive to save you time at every step along the Breast Health Continuum of Care.

Our pioneering, integrated technologies help you deliver maximum clinical confidence, workflow efficiencies, and an enhanced patient experience to advance the earlier diagnosis of breast cancer.

Hologic, your trusted Breast and Skeletal Health partner.



To learn more about the full range of Tumark breast biopsy markers please visit: www.hologic.co.uk

References

1. Data on File with Hologic: MISC-07876, Attachment 2, Attachment 45
2. Data on File with Hologic: DHM-06169.
3. Data on File with Hologic: MISC-07876 Attachment 2.
4. Rüländ AM, Hagemann F, Reinisch M, Holtschmidt J, Kümmler A, Dittmer-Grabowski C *et al*. Using a New Marker Clip System in Breast Cancer: Tumark Vision® Clip - Feasibility Testing in Everyday Clinical Practice. *Breast Care (Basel)*. 2018;13(2):116–120.
5. Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT *et al*. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2019;30(8):1194-1220.
6. Bick U, Trimboli RM, Athanasiou A, Balleyguier C, Baltzer PAT, Bernathova M *et al*. Image-guided breast biopsy and localisation: recommendations for information to women and referring physicians by the European Society of Breast Imaging. *Insights Imaging*. 2020;11(1):12.
7. Public Health England [Internet]. NHS Breast Screening Programme Clinical guidelines for breast cancer screening assessment: fourth edition. 2025. Available from: <https://www.gov.uk/government/publications/breast-screening-clinical-guidelines-for-screening-management>.
8. Thomassin-Naggara I, Lalonde L, David J, *et al*. A plea for the Biopsy marker: How, why and why not clipping after breast biopsy? *Breast Cancer Res Treat*. 2012;132(3):881-893.
9. Hologic Data on File: MISC-08002 Rev001, Attachments 2, 3, 10.

CE 2797 Brevera®, Eviva®
0482



Hologic BV, Da Vincilaan 5, 1930 Zaventem, Belgium

Breast & Skeletal Health | Hologic.co.uk | euinfo@hologic.com

PB-01157-EUR-2101 Rev 001 © 2025 Hologic, Inc. All rights reserved. Brevera, Eviva and Tumark and associated logos are trademarks or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. This information is intended for medical professionals and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshow, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, please contact your local Hologic representative or write to euinfo@hologic.com.